Cadila Healthcare is currently trading at Rs 747.80, up by 6.45 points or 0.87% from its previous closing of Rs 741.35 on the BSE.
The scrip opened at Rs 749.00 and has touched a high and low of Rs 750.85 and Rs 746.05 respectively. So far 253 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 964.00 on 12-Sep-2012 and a 52 week low of Rs 695.00 on 16-Apr-2012.
Last one week high and low of the scrip stood at Rs 750.85and Rs 714.20 respectively. The current market cap of the company is Rs 15179.03 crore.
The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 16.32% and 8.89% respectively.
Zydus Cadila has received tentative approval from the USFDA for Amlodipine Besylate and Benazepril Hydrochloride capsules, which fall under the anti-hypertensive drug segment. The company received US Food and Drug Administration’s (USFDA) tentative nod for the formulation in the strengths of 2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg and 10 mg/20 mg.
As per IMS, the estimated sale for Amlodipine Besylate and Benazepril Hydrochloride capsules in 2012 was $384.8 million.
The group now has 78 approvals and has so far filed 173 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-04.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1462.50 |
Dr. Reddys Lab | 5784.50 |
Cipla | 1451.25 |
Zydus Lifesciences | 1001.15 |
Lupin | 1587.90 |
View more.. |